AHCLNSEAnlon Healthcare Limited· Pharmaceuticals & BiotechnologyHighNeutral
Announced Mon, 9 Feb, 2026 · 15:58 IST

Anlon Healthcare Q3 PAT at 515.54L, Revenue drops 32% YoY, CFO and Director changes

AHCL · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-2.4%Reaction day
₹12.68
prior close
₹12.87
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used+1.0%-3.4% vs market
Pharmaceuticals peers, median of 159sector+0.4%-2.9% vs sector

On the reaction day the stock moved 3.4 pts less than Nifty Microcap 250 and 2.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
-1.1
10m
-1.7
15m
-1.7
30m
-2.1
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-2.4+1.0-3.4+0.4-2.9
Next day
-3.0+0.5-3.5+0.3-3.3
2d
-3.9-0.0-3.9+0.0-3.9
3d
-4.6-1.5-3.1-1.2-3.4
4d
-4.8-2.2-2.6-1.7-3.1
5d
-3.9-1.2-2.7-1.8-2.2
1w
-7.7-2.4-5.4-2.5-5.2
15d
-14.0-8.8-5.2-6.9-7.1
1m
-1.1-8.3+7.2-5.1+4.0
2m
+2.2-3.5+5.8-3.5+5.7
3m
+12.0+6.4+5.6+2.8+9.2
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 159Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Board meeting on Feb 9, 2026 approved Q3 FY26 results. Q3 revenue fell to 3,557.80 lakhs from 5,220.13 lakhs YoY, a 32% drop. Q3 PAT was 515.54 lakhs vs 931.73 lakhs. 9M PAT was 1,801.96 lakhs. CFO Hitesh Makwana resigned due to pre-occupation; Naimish Bhatt named new CFO. Independent Director Shailesh Thakkar resigned citing health issues; Kishan Raja appointed as new Independent Director. IPO funds of 12,103 lakhs used as planned.

Likely market impact

Weak Q3 results with sharp revenue and profit decline may pressure stock. Management changes add uncertainty.